Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | ARF6 | P62330 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275351 | 0.88 | RAD51 (0.35) | MAPTTHRBADORA2AADORA2BADORA1 | |
| SCHEMBL10276360 | 0.87 | KDM4E (0.36) | MAPTTHRBADORA2AADORA2BADORA1 | |
| SCHEMBL10275424 | 0.79 | NPC1 (0.46) | ADORA1 | |
| SCHEMBL10313576 | 0.79 | ADORA1 (0.40) | ADORA2AADORA2BADORA1 | |
| SCHEMBL10275202 | 0.74 | MAPT (0.39) | MAPTTP53 | |
| SCHEMBL10275378 | 0.74 | NPC1 (0.38) | MAPTTHRB | |
| SCHEMBL10276069 | 0.74 | MAPT (0.49) | MAPTALDH1A1BRD4TP53 | |
| SCHEMBL10275521 | 0.73 | AR (0.36) | ALDH1A1BRD4 | |
| SCHEMBL10276280 | 0.71 | ARF6 (0.41) | MAPTARF6ALDH1A1 | |
| SCHEMBL10275665 | 0.71 | CFTR (0.38) | MAPTTHRBLMNAARF6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | MAPT 750/4885THRB 1178/4885LMNA 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.